Loading
Metabolism, Diabetes, and Cancer / Muscle Physiology and Disorders · Journal article
Frontiers in Endocrinology · September 7, 2026
Raises a question worth testing. It does not answer one.
This is a hypothesis-generating narrative review proposing myosteatosis as an immunometabolic phenotype in type 1 diabetes, centered on dysregulation of the AMPK-PPAR-mitochondrial axis coupled with chronic immune activation and lipotoxicity. The authors explicitly state that direct mechanistic evidence from T1D skeletal muscle is scarce and their framework is assembled substantially by inference from type 2 diabetes, obesity, and ageing models, thereby defining a research agenda rather than asserting validated T1D-specific mechanisms.
Narrative review. Type 1 diabetes; framework also incorporates evidence from type 2 diabetes, obesity, and ageing models.
In T1D, chronic immune activation and metabolic stress suppress AMPK and PPARδ signaling, impair PGC-1α–dependent mitochondrial function, and reduce oxidative capacity, promoting intramyocellular lipid accumulation despite preserved muscle mass Myosteatosis is reinforced by persistent inflammatory signaling (IL-6, TNF-α, IL-1β; NF-κB, JNK, and NLRP3 pathways), accumulation of lipotoxic intermediates (ceramides and diacylglycerols), and dysregulated myokine secretion (increased myostatin with reduced IL-15 and irisin) Mitochondrial stress is reflected by impaired phosphocreatine recovery, altered acylcarnitine profiles, increased oxidative damage, and reduced NAD+-SIRT1/3 activity
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies potential therapeutic targets (AMPK-PPAR-mitochondrial axis and its inflammatory and lipotoxic modifiers) that may enable earlier detection and mechanism-based interventions to preserve muscle metabolic resilience in T1D; however, the mechanistic claims remain hypothesis-generating pending direct validation in T1D skeletal muscle.
This is a narrative review synthesizing evidence from multiple disease models to generate a mechanistic framework for myosteatosis in T1D; the authors explicitly state direct mechanistic data from T1D skeletal muscle are scarce and the framework is deliberately hypothesis-generating, assembled substantially by inference from T2D, obesity, and ageing models.
As stated by the source record.
This review identifies potential therapeutic targets (AMPK-PPAR-mitochondrial axis and its inflammatory and lipotoxic modifiers) that may enable earlier detection and mechanism-based interventions to preserve muscle metabolic resilience in T1D; however, the mechanistic claims remain hypothesis-generating pending direct validation in T1D skeletal muscle.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Myosteatosis, defined as pathological lipid accumulation within and between skeletal muscle fibers, is increasingly recognized as a determinant of impaired muscle quality, metabolic inflexibility, and adverse clinical outcomes. Although well described in ageing, obesity, and cancer, its relevance to type 1 diabetes (T1D) remains underexplored. T1D is characterized by lifelong insulin deficiency, persistent autoimmune activation, and glycemic variability, conditions that profoundly disrupt cellular energy metabolism and substrate utilization in skeletal muscle, even in the absence of obesity or overt sarcopenia. This review integrates evidence from human imaging, metabolic phenotyping, immunological profiling, and multi-omics analyses to define myosteatosis as an immunometabolic phenotype in T1D. Central to this framework is dysregulation of the AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor (PPAR)-mitochondrial axis, which normally coordinates fatty-acid oxidation, mitochondrial biogenesis, and energy efficiency in skeletal muscle. In T1D, chronic immune activation and metabolic stress suppress AMPK and PPARδ signaling, impair PGC-1α–dependent mitochondrial function, and reduce oxidative capacity, promoting intramyocellular lipid accumulation despite preserved muscle mass. These defects are reinforced by persistent inflammatory signaling (IL-6, TNF-α, IL-1β; NF-κB, JNK, and NLRP3 pathways), accumulation of lipotoxic intermediates (ceramides and diacylglycerols), dysregulated myokine secretion (increased myostatin with reduced IL-15 and irisin), and infiltration of pro-inflammatory macrophages and CD8 + T cells. Mitochondrial stress, reflected by impaired phosphocreatine recovery, altered acylcarnitine profiles, increased oxidative damage, and reduced NAD + –SIRT1/3 activity, further consolidates immunometabolic dysfunction and lipid deposition. Collectively, this review positions myosteatosis as a clinically relevant and potentially modifiable consequence of immune-driven failure of cellular energy utilization in T1D. Because direct mechanistic data from T1D skeletal muscle remain scarce, the framework presented here is deliberately hypothesis-generating: it is assembled substantially by inference from type 2 diabetes (T2D), obesity and ageing models, and we map the resulting evidence gaps explicitly in order to define a research agenda rather than to assert a validated T1D-specific mechanism. Targeting the AMPK-PPAR-mitochondrial axis and its inflammatory and lipotoxic modifiers may enable earlier detection and mechanism-based interventions to preserve muscle metabolic resilience and functional capacity in autoimmune diabetes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.